Two biosimilar approvals in less than a month have extended Pfizer Inc.’s already dominant position in the US biosimilars space, bringing the big pharma’s tally of 351(k) biologics license application approvals to seven – accounting for almost one-third of the FDA’s total of 23 approvals using the biosimilar pathway.
The FDA approved Pfizer’s Ruxience (rituximab-pvvr) on 23 July 2019 after clearing the company’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?